Until today, two cases in which Spiromastix mold fungus was isolated as a causative agent have been reported in the literature, and our case is the first case reported from Turkey.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Invasive fungal infections (IFIs) are an important cause of morbidity and mortality, especially in patients with hematological malig- nancies and immunodeficiency.
📊
Key Findings & Data:In this case report, an 80-year-old male patient with a diagnosis of acute myeloid leukemia who received remission induction chemotherapy, followed by liposomal Amphotericin B treat- ment after posaconazole prophylaxis, developed invasive pulmonary fungal infection with Spiromastix fungus mold and was treated successfully with voriconazole.
💡
Conclusion & Impact:Until today, two cases in which Spiromastix mold fungus was isolated as a causative agent have been reported in the literature, and our case is the first case reported from Turkey.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Invasive fungal infections (IFIs) are an important cause of morbidity and mortality, especially in patients with hematological malig- nancies and immunodeficiency. Although Aspergillus mold fungi are the most common cause of IFI in this patient group, it has been reported recently in various publications that rare molds may also be the cause. In this case report, an 80-year-old male patient with a diagnosis of acute myeloid leukemia who received remission induction chemotherapy, followed by liposomal Amphotericin B treat- ment after posaconazole prophylaxis, developed invasive pulmonary fungal infection with Spiromastix fungus mold and was treated successfully with voriconazole. Until today, two cases in which Spiromastix mold fungus was isolated as a causative agent have been reported in the literature, and our case is the first case reported from Turkey.
🔖
Cite This Article
AKSARAY, S., ÖZAKKAŞ, F., DOĞAN, Ö., ÇAĞ, Y., SOYSAL, E., TURAN, D. (2022). Invasive Pulmonary Fungal Infection Caused by the Fungus Spiromastix in an Immunosuppressive Patient. Haydarpaşa Numune Medical Journal, Cilt: 61 - Sayı: 3, 361–366. https://ajindex.com/articles/535937
Stchigel AM, Sutton DA, Cano-Lira JF, Wiederhold N, Guarro J. New species spiromastigoides albida from a lung biopsy. My- copathologia 2017;182:967–78
Rizzo L, Sutton DA, Wiederhold NP, Thompson EH, Friedman R, Wickes BL, et al. Isolation and characterisation of the fun- gus Spiromastix asexualis sp. nov. from discospondylitis in a German Shepherd dog, and review of Spiromastix with the proposal of the new order Spiromastixales (Ascomycota). My- coses 2014;57:419–28
Colombo AL, de Almeida Júnior JN, Slavin MA, Chen SC, Sorrell TC. Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. Lancet Infect Dis 2017;17:e344–56
J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, et al. Posaconazole vs. fluconazole or itracona- zole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348–59 5. Cho SY, Lee DG, Choi SM, Choi JK, Lee HJ, Kim SH, et al. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations. My- coses 2015;58:565–71
Pagano L, Busca A, Candoni A, Cattaneo C, Cesaro S, Fanci R, et al. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Rev 2017;31:17–29
Prasad A, Agarwal K, Deepak D, Atwal SS. Pulmonary Aspergillosis: what CT can offer before it is too Late! J Clin Di- agn Res 2016;10:TE01–5
Arendrup MC, Bille J, Dannaoui E, Ruhnke M, Heussel CP, Kib- bler C. ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia. Bone Marrow Transplant 2012;47:1030–45
Chabi ML, Goracci A, Roche N, Paugam A, Lupo A, Revel MP. Pulmonary aspergillosis. Diagn Interv Imaging 2015;96:435–42
Tortorano AM, Esposto MC, Prigitano A, Grancini A, Ossi C, Cavanna C, et al. Cross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol 2012;50:1051–3
Kebabcı N, van Diepeningen AD, Ener B, Ersal T, Meijer M, Al- Hatmi AM, et al. Fatal breakthrough infection with Fusarium andiyazi: new multi-resistant aetiological agent cross-react- ing with Aspergillus galactomannan enzyme immunoassay. Mycoses 2014;57:249–55 12. ECIL 5, Primary Antifungal Prophylaxis, September 19-21, 2013. Avilable at: http:/